Catharanthine Tartrate(CAS: 4168-17-6)

Catharanthine Tartrate (CAS: 4168-17-6) must comply with regulatory guidelines such as REACH in the EU, which requires registration, evaluation, and authorization for certain chemicals. In the US, it falls under the jurisdiction of the FDA for pharmaceutical applications and the EPA for environmental and safety concerns. It is also classified according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS).

Alternatives to Catharanthine Tartrate (CAS: 4168-17-6) in synthesis include other alkaloids such as vinblastine and epothilone, as well as synthetic analogs. These alternatives can be used based on specific requirements and availability in the market. Common reagents include various amines, aldehydes, and alcohols, depending on the desired chemical transformation.

Research on Catharanthine Tartrate (CAS: 4168-17-6) is focused on its potential as an antitumor agent, particularly in cancer therapy. Market trends indicate a growing interest in natural product-derived drugs, with increasing emphasis on its anticancer properties. Studies are also exploring its use in combination therapies and as a potential immunomodulator.

Waste containing Catharanthine Tartrate (CAS: 4168-17-6) should be managed according to local and international hazardous waste regulations. This includes proper collection, storage, and disposal, potentially involving incineration or professional waste disposal services. Environmental protection measures such as minimizing spillage and ensuring proper labeling of containers are crucial to prevent contamination and ensure safety.